These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8820460)

  • 1. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
    Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin/tazobactam: a critical review of the evolving clinical literature.
    Sanders WE; Sanders CC
    Clin Infect Dis; 1996 Jan; 22(1):107-23. PubMed ID: 8824974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM; Brogden RN
    Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
    Perry CM; Markham A
    Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
    Vestweber KH; Grundel E
    Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
    Sörgel F; Kinzig M
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():39-60. PubMed ID: 8383655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A combined dosage form of piperacillin and tazobactam--tazocin].
    Iakovlev SV
    Antibiot Khimioter; 1997; 42(2):5-16. PubMed ID: 9124994
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
    Sörgel F; Kinzig M
    Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections.
    Mouton Y; Leroy O; Beuscart C; Chidiac C; Senneville E; Ajana F; Lecocq P
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():87-95. PubMed ID: 8383658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fundamental and clinical studies on tazobactam/piperacillin in the pediatric field].
    Kitamura K; Nishimori H; Ihara T; Kamiya H
    Jpn J Antibiot; 1998 Jun; 51(6):407-12. PubMed ID: 9755830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
    Jones RN
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bacteriological and clinical evaluation tazobactam/piperacillin in infectious diseases in surgical field].
    Shinagawa N; Yura J; Mashita K; Matsuno S; Rikiyama T; Hirayama T; Tanaka T; Otsuka K; Iwai S; Nakagawa Y
    Jpn J Antibiot; 1995 Mar; 48(3):346-67. PubMed ID: 7752449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
    Leleu G; Kitzis MD; Vallois JM; Gutmann L; Decazes JM
    Antimicrob Agents Chemother; 1994 Feb; 38(2):195-9. PubMed ID: 8192442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.